These are frustrating days to be a med-tech investor. Companies with
high-quality products and growth are generally trading at pretty extreme
multiples, while the low-multiple companies tend to be those with some
pretty serious operational/competitive issues. AngioDynamics (ANGO)
seems to be somewhere in the middle - the company's underlying business
is muddling along through some challenging times in its addressed
markets, while the valuation isn't quite in clear value range.
Please read more here:
AngioDynamics Stuck In That Difficult Grey Area
No comments:
Post a Comment